Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 3:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1801–1824 of 10,816 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Developmental Defect Clear all
Completed Not applicable Interventional

Resiliency Training for Patients With NF2 Via Videoconferencing With Skype

NCT02811718
View directory record Official record
Conditions
Neurofibromatosis 2
Interventions
Stress Management Group 1, Stress Management Group 2
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 17, 2018 · Synced Oct 31, 2026, 3:02 AM EDT
Withdrawn Phase 4 Interventional

Visceral Artery Aneurysm Embolization by the Penumbra Ruby™ Coil System

NCT02079818
View directory record Official record
Conditions
Visceral Artery Aneurysms, Arteriovenous Malformations
Interventions
Penumbra Ruby Coil System
Device
Lead sponsor
Penumbra Inc.
Industry
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 12, 2019 · Synced Oct 31, 2026, 3:02 AM EDT
Completed Not applicable Interventional

Multicenter Investigation of the Glaukos® Suprachoroidal Stent Model G3 In Conjunction With Cataract Surgery

NCT01461278
View directory record Official record
Conditions
Primary Open-angle Glaucoma
Interventions
iStent supra, Cataract surgery
Device · Procedure
Lead sponsor
Glaukos Corporation
Industry
Eligibility
45 Years and older
Enrollment
505 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
1
States / cities
Racine, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 19, 2022 · Synced Oct 31, 2026, 3:02 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Safety and Efficacy Study of GEB-101 Injection in Subjects With TGFBI-related Corneal Dystrophy

NCT07750678
View directory record Official record
Conditions
Hereditary Corneal Dystrophy, Corneal Abnormality, Corneal Dystrophies, Corneal Dystrophies, Hereditary
Interventions
GEB-101 Injection
Genetic
Lead sponsor
GenEditBio Limited
Industry
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 31, 2026, 3:02 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Technical and Translational Development of Cardiovascular Magnetic Resonance (CMR) Imaging

NCT03581318
View directory record Official record
Conditions
Normal and Abnormal Cardiovascular Physiology
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
7 Years to 100 Years
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 31, 2026, 3:02 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety of Simvastatin in LAM and TSC

NCT02061397
View directory record Official record
Conditions
Lymphangioleiomyomatosis, Tuberous Sclerosis Complex
Interventions
Simvastatin, Sirolimus Oral Product, Everolimus Oral Product
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 25, 2020 · Synced Oct 31, 2026, 3:02 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Open Label PK, PD and DDI of Dotinurad and Allopurinol in Gout Patients With Hyperuricemia

NCT06056570
View directory record Official record
Conditions
Gout, Hyperuricemia
Interventions
dotinurad, dotinurad + allopurinol, allopurinol
Drug
Lead sponsor
Urica Therapeutics Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
4
States / cities
Clearwater, Florida • Miami Lakes, Florida • Mesquite, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 31, 2026, 3:02 AM EDT
Completed Not applicable Interventional

Clinical Trial of a Serious Game for Individuals With SCI/D

NCT02341950
View directory record Official record
Conditions
Spinal Cord Injury, Spinal Cord Involvement, Spina Bifida, Transverse Myelitis, Polio and Post-polio Syndrome, Syringomyelia, Spinal Stenosis, Spinal Neoplasms, Spinal Cord Diseases
Interventions
SCI Hard
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
13 Years to 29 Years
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 22, 2019 · Synced Oct 31, 2026, 3:02 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Global and Regional Myocardial Strain and Power Output In Patients With Single Ventricles Using Novel MRI Techniques

NCT01107990
View directory record Official record
Conditions
Fontan Procedure, Hypoplastic Left Heart Syndrome, Tricuspid Atresia, Double Inlet Left Ventricle
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
10 Years and older
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 21, 2020 · Synced Oct 31, 2026, 3:02 AM EDT
Terminated Phase 3 Interventional Results available

The Hemophilia Inhibitor Prevention Trial

NCT04303559
View directory record Official record
Conditions
Hemophilia A Without Inhibitor
Interventions
Eloctate Injectable Product, Emicizumab Injection [Hemlibra]
Drug
Lead sponsor
Margaret Ragni
Other
Eligibility
4 Months to 4 Years · Male only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
Little Rock, Arkansas • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 11, 2023 · Synced Oct 31, 2026, 3:02 AM EDT
Recruiting Phase 2 Interventional

Evaluating VM100 Nutritional Supplement for Improving Quality of Life in Duchenne Muscular Dystrophy Patients

NCT07766980
View directory record Official record
Conditions
Duchenne Muscular Dystrophy, Duchenne Disease, Muscular Dystrophy in Children, DMD, Muscular Dystrophy
Interventions
VM100 Nutritional Supplement
Drug
Lead sponsor
University of Florida
Other
Eligibility
6 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 31, 2026, 3:02 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Prospective Evaluation of Infants With Spinal Muscular Atrophy:

NCT02831296
View directory record Official record
Conditions
Spinal Muscular Atrophy
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 2, 2020 · Synced Oct 31, 2026, 3:02 AM EDT
Terminated Phase 3 Interventional

A Study Evaluating the Long-Term Safety of ICA-17043 in Sickle Cell Disease Patients With or Without Hydroxyurea Therapy

NCT00294541
View directory record Official record
Conditions
Sickle Cell Disease, Sickle Cell Anemia
Interventions
ICA-17043
Drug
Lead sponsor
Icagen
Industry
Eligibility
17 Years to 66 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
31
States / cities
Mobile, Alabama • Little Rock, Arkansas • Oakland, California + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2007 · Synced Oct 31, 2026, 3:02 AM EDT
Completed Phase 1 Interventional

AAV2/8-LSPhGAA (ACTUS-101) in Late-Onset Pompe Disease

NCT03533673
View directory record Official record
Conditions
Pompe Disease
Interventions
ACTUS-101
Genetic
Lead sponsor
AskBio Inc
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 31, 2026, 3:02 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Evaluate the Safety and Clinical Activity of Intramuscular Doses of BB-301 Administered to Subjects With Oculopharyngeal Muscular Dystrophy With Dysphagia

NCT06185673
View directory record Official record
Conditions
Oculopharyngeal Muscular Dystrophy
Interventions
BB-301: Dose escalation phase 1b cohort 1, BB-301: Dose escalation phase 1b cohort 2, BB-301: Dose escalation phase 1b cohort 3, BB-301: Dose expansion phase 2a
Genetic
Lead sponsor
Benitec Biopharma, Inc.
Industry
Eligibility
Up to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2040
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 31, 2025 · Synced Oct 31, 2026, 3:02 AM EDT
Active, not recruiting Phase 3 Interventional

A Clinical Study to Evaluate the Use of a Cryopreserved Formulation of OTL-103 in Subjects With Wiskott-Aldrich Syndrome

NCT03837483
View directory record Official record
Conditions
Wiskott-Aldrich Syndrome
Interventions
OTL-103
Genetic
Lead sponsor
Fondazione Telethon
Other
Eligibility
Up to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Oct 31, 2026, 3:02 AM EDT
Completed No phase listed Observational

Peak Cough Flow and Cough Clearance in Patients With Muscular Dystrophy

NCT02034305
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
6 Years to 21 Years · Male only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 5, 2024 · Synced Oct 31, 2026, 3:02 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Device for Improving Skin Quality and Texture on the Face and Neck

NCT06645366
View directory record Official record
Conditions
Wrinkle, Pigmentation, Skin Laxity, Skin Scarring
Interventions
Treatment with BTL-785F
Device
Lead sponsor
BTL Industries Ltd.
Industry
Eligibility
22 Years and older
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
3
States / cities
Greenwood Village, Colorado • Chevy Chase, Maryland • Birmingham, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Oct 31, 2026, 3:02 AM EDT
Completed Phase 2 Interventional Results available

Study To Assess Efficacy, Safety, Tolerability And Pharmacokinetics Of PF-07038124 Ointment In Participants With Atopic Dermatitis Or Plaque Psoriasis

NCT04664153
View directory record Official record
Conditions
Atopic Dermatitis, Plaque Psoriasis
Interventions
PF-07038124 ointment, Vehicle ointment
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
15
States / cities
Fountain Valley, California • Cape Coral, Florida • Clearwater, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2022 · Synced Oct 31, 2026, 3:02 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX

NCT03366337
View directory record Official record
Conditions
IgA Nephropathy, CKD Associated With Type 1 Diabetes, Focal Segmental Glomerulosclerosis, Autosomal Dominant Polycystic Kidney
Interventions
Bardoxolone methyl capsules
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 65 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
30
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2025 · Synced Oct 31, 2026, 3:02 AM EDT
Completed Phase 2 Interventional Results available

Busulfan and Etoposide Followed by Peripheral Blood Stem Cell Transplant and Low-Dose Aldesleukin in Treating Patients With Acute Myeloid Leukemia

NCT00003875
View directory record Official record
Conditions
Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Childhood Acute Myeloid Leukemia in Remission, Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Myeloid Leukemia
Interventions
busulfan, etoposide, aldesleukin, peripheral blood stem cell transplantation
Drug · Biological · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2015
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 5, 2017 · Synced Oct 31, 2026, 3:02 AM EDT
Recruiting Phase 2 Interventional

A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT

NCT04322318
View directory record Official record
Conditions
Anaplastic Kidney Wilms Tumor, Recurrent Kidney Wilms Tumor, Stage II Kidney Wilms Tumor, Stage III Kidney Wilms Tumor, Stage IV Kidney Wilms Tumor
Interventions
Biopsy Procedure, Biospecimen Collection, Bone Scan, Carboplatin, Computed Tomography, Cyclophosphamide, Doxorubicin, Etoposide, Ifosfamide, Irinotecan, Magnetic Resonance Imaging, Positron Emission Tomography, Radiation Therapy, Surgical Procedure, Topotecan, Transabdominal Ultrasound, Vincristine, X-Ray Imaging
Procedure · Drug · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 30 Years
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
178
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 138 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 31, 2026, 3:02 AM EDT
Completed Phase 3 Interventional Results available

Surfactant Positive Airway Pressure and Pulse Oximetry Trial

NCT00233324
View directory record Official record
Conditions
Infant, Newborn, Diseases, Other Preterm Infants, Infant, Small for Gestational Age, Premature Birth, Bronchopulmonary Dysplasia, Retinopathy of Prematurity
Interventions
Surfactant, Continuous Positive Airway Pressure (CPAP), Supplemental oxygen with target saturation of 85 to 89%, Supplemental oxygen with target saturation of 91 to 95%
Drug · Device
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
24 Weeks to 27 Weeks
Enrollment
1,316 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2016
U.S. locations
22
States / cities
Birmingham, Alabama • Palo Alto, California • San Diego, California + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2019 · Synced Oct 31, 2026, 3:02 AM EDT
Completed Phase 2 Interventional

Bucillamine for the Treatment of Acute Gout Flare in Subjects With Moderate to Severe Gout

NCT02330796
View directory record Official record
Conditions
Gout
Interventions
Bucillamine, Colchicine
Drug
Lead sponsor
Revive Therapeutics, Ltd.
Industry
Eligibility
18 Years to 80 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
3
States / cities
San Roman, California • Arlington, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 5, 2016 · Synced Oct 31, 2026, 3:02 AM EDT